Modulation of genes involved in zinc homeostasis in old low-grade atherosclerotic patients under effects of HMG-CoA reductase inhibitors.
Taking into account the antioxidant properties of zinc, it is difficult to explain the beneficial effects of HMG-CoA reductase inhibitors in the context of a well-known decreased zinc status. Therefore, intracellular zinc homeostasis was studied in patients with low-grade carotid atherosclerosis under treatment with HMG-CoA reductase inhibitors using a custom microarray-based approach developed by pooling information across microarray studies. Experimental data unravel an active zinc signaling in PBMC from low-grade atherosclerotic patients under lipid reduction therapy, suggesting that monitoring intracellular zinc status could be a key factor for an optimal strategy and targeting a level of intervention.
Costarelli
Laura
L
Immunology Center, Section of Nutrition, Immunity and Ageing, Research Department, INRCA, Ancona, Italy. lauracostarelli@hotmail.com
Muti
Elisa
E
Malavolta
Marco
M
Giacconi
Robertina
R
Cipriano
Catia
C
Sartini
Davide
D
Emanuelli
Monica
M
Silvestrini
Mauro
M
Provinciali
Leandro
L
Gobbi
Beatrice
B
Mocchegiani
Eugenio
E
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000235:genetics*; D050197:Atherosclerosis / Q000188:drug therapy* / Q000235:genetics*; D016022:Case-Control Studies; D005260:Female; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation; D006706:Homeostasis / Q000235:genetics*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D015203:Reproducibility of Results; D015032:Zinc / Q000378:metabolism*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D015032:Zinc